Jose C. Tapia, Freya Bosma, J. Gavira, Sofia Sanchez, Maria Alejandra Molina, J. Sanz-Beltran, Cristina Martín-Lorente, G. Anguera, Pablo Maroto
{"title":"转移性尿路上皮癌患者使用免疫检查点抑制剂前后的治疗模式和生存结果:2004 年至 2021 年的一项单中心回顾性研究。","authors":"Jose C. Tapia, Freya Bosma, J. Gavira, Sofia Sanchez, Maria Alejandra Molina, J. Sanz-Beltran, Cristina Martín-Lorente, G. Anguera, Pablo Maroto","doi":"10.1016/j.clgc.2024.01.019","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic urothelial carcinoma: A single-centre retrospective study from 2004 to 2021.\",\"authors\":\"Jose C. Tapia, Freya Bosma, J. Gavira, Sofia Sanchez, Maria Alejandra Molina, J. Sanz-Beltran, Cristina Martín-Lorente, G. Anguera, Pablo Maroto\",\"doi\":\"10.1016/j.clgc.2024.01.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":93941,\"journal\":{\"name\":\"Clinical genitourinary cancer\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical genitourinary cancer\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clgc.2024.01.019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1016/j.clgc.2024.01.019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic urothelial carcinoma: A single-centre retrospective study from 2004 to 2021.